Role of CYP2C9 polymorphism in losartan oxidation

Drug Metabolism and Disposition

Volumn 29, Issue 7, 2001, Pages 1051-1056

  Yasar, Ümit ^a   Tybring, Gunnel ^a   Hidestrand, Mats ^b   Oscarson, Mikael ^b   Ingelman Sundberg, Magnus ^b   Dahl, Marja Liisa ^a   Eliasson, Erik ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; LOSARTAN;

ARTICLE; DRUG ACTIVATION; DRUG OXIDATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN TISSUE; LIVER MICROSOME; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIHYPERTENSIVE AGENTS; ARYL HYDROCARBON HYDROXYLASES; BASE SEQUENCE; CYTOCHROME P-450 ENZYME SYSTEM; DICLOFENAC; DNA PRIMERS; HUMANS; LOSARTAN; OXIDATION-REDUCTION; POLYMORPHISM, GENETIC; RECEPTORS, ANGIOTENSIN; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES;

EID: 0034951038     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
2. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin
3. Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron
4. Evaluation of triacetyloleandomycin, alpha-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450
5. The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:Cytochrome P450 oxidoreductase
6. Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences
7. Direct injection of large volumes of plasma/serum on a new biocompatible extraction column for the determination of atenolol, propranolol and ibuprofen. Mechanisms for the improvement of chromatographic performance
8. Multiple forms of human P450 expressed in Saccharomyces cerevisiae. Systematic characterization and comparison with those of the rat
9. Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174
10. Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers
11. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
12. Specificity of in vitro covalent binding of tienilic acid metabolites to human liver microsomes in relationship to the type of hepatotoxicity: Comparison with two directly hepatotoxic drugs
13. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans
14. Protein measurements with the Folin phenol reagent
15. Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174
16. The effects of fluvastatin, a CYP2C9 inhibitor, on losartan pharmacokinetics in healthy volunteers
17. Use of tolbutamide as a substrate probe for human hepatic cytochrome P450 2C9
18. Cytochrome P4502C9: An enzyme of major importance in human drug metabolism
19. The carbon monoxide-binding pigment of liver microsomes. I. Evidence of its hemoprotein nature
20. A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function
21. An improved method for the simultaneous determination of losartan and its major metabolite, EXP3174, in human plasma and urine by high-performance liquid chromatography with fluorescence detection
22. Lack of polymorphism of the conversion of losartan to its active metabolite E-3174 in extensive and poor metabolizers of debrisoquine (cytochrome P450 2D6) and mephenytoin (cytochrome P450 2C19)
23. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians
24. A mutation in CYP2C9 is responsible for decreased metabolism of losartan
25. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members
26. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism
27. CYP2C9 Ile359 and Leu359 variants: Enzyme kinetic study with seven substrates
28. Angiotensin II receptors and angiotensin II receptor antagonists
29. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications
30. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors
31. Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects
32. Maximizing the expression of mammalian cytochrome P-450 monooxygenase activities in yeast cells
33. Drug metabolism in human liver in vitro: Establishment of a human liver bank
34. Interindividual differences in hepatic expression of CYP3A4: Relationship to genetic polymorphism in the 5′-upstream regulatory region
35. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes
36. Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes
37. Comparative studies of in vitro inhibition of cytochrome P450 3A4- dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin
38. Validation of methods for CYP2C9 genotyping: Frequencies of mutant alleles in a Swedish population
39. Some properties of a detergent-solubilized NADPH-cytochrome c (cytochrome P-450) reductase purified by biospecific affinity chromatography
40. Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174